Ivan Babic
Overview
Explore the profile of Ivan Babic including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
1232
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Foote J, Mattox T, Keeton A, Chen X, Smith F, Berry K, et al.
Cancer Res
. 2024 Dec;
85(5):956-972.
PMID: 39700396
Activated RAS is a common driver of cancer that was considered undruggable for decades. Recent advances have enabled the development of RAS inhibitors, but the efficacy of these inhibitors remains...
2.
Ozcan Tezgin D, Kurkcu S, Si D, Krucinska J, Mosley A, Mehta P, et al.
Biochem Pharmacol
. 2024 Nov;
230(Pt 3):116617.
PMID: 39528074
Cellular resistance can limit the effectiveness of antifolate drugs for the treatment of cancer and autoimmune diseases. We examined the biochemical and cellular effects of a propargyl linked, non-classical antifolate...
3.
Carrillo J, Gill J, Redfern C, Babic I, Nomura N, Shah D, et al.
Neurooncol Adv
. 2024 Oct;
6(1):vdae166.
PMID: 39465217
Background: This phase 1 (NCT04396717) open-label, multicenter study, evaluated Pritumumab, a IgG1 monoclonal antibody, in patients with gliomas and brain metastases. The primary objective was to evaluate the safety and/or...
4.
Foote J, Mattox T, Keeton A, Chen X, Smith F, Berry K, et al.
bioRxiv
. 2024 Feb;
PMID: 38328254
Significance: ADT-007 has unique pharmacological properties with distinct advantages over other RAS inhibitors by circumventing resistance and activating antitumor immunity. ADT-007 prodrugs and analogs with oral bioavailability warrant further development...
5.
Kovac M, Tadic V, Kralj J, Perisa M, Oreskovic S, Babic I, et al.
Biomed Pharmacother
. 2023 Aug;
166:115349.
PMID: 37634476
Background: DNA methylation, histone modifications, and miRNAs affect ovarian cancer (OC) progression and therapy response. Purpose: Identification of epigenetically downregulated miRNAs in drug-resistant OC cell lines with a possible role...
6.
Vujic G, Mikus M, Matak L, Bonevski A, Babic I, Planinic P, et al.
Rev Bras Ginecol Obstet
. 2020 Jun;
42(5):297-302.
PMID: 32483810
Objective: Desmoplastic small round cell tumor (DSRCT) is a rare intraabdominal neoplasm that grows along serosal surfaces and is primarily found in young men. To date, only 16 cases of...
7.
Rodvold J, Xian S, Nussbacher J, Tsui B, Waller T, Searles S, et al.
Sci Rep
. 2020 May;
10(1):8348.
PMID: 32433555
To date current therapies of glioblastoma multiforme (GBM) are largely ineffective. The induction of apoptosis by an unresolvable unfolded protein response (UPR) represents a potential new therapeutic strategy. Here we...
8.
Cheltsov A, Nomura N, Yenugonda V, Roper J, Mukthavaram R, Jiang P, et al.
Sci Rep
. 2020 May;
10(1):8096.
PMID: 32415084
Abnormal regulation of β-catenin initiates an oncogenic program that serves as a main driver of many cancers. Albeit challenging, β-catenin is an attractive drug target due to its role in...
9.
Her N, Babic I, Yenugonda V, Kesari S, Nurmemmedov E
Biotechniques
. 2020 Feb;
68(4):180-184.
PMID: 32040335
CRISPR-Cas9 has proven to be a versatile tool for the discovery of essential genetic elements involved in various disease states. CRISPR-assisted dense mutagenesis focused on therapeutically challenging protein complexes allows...
10.
Babic I, Kesari S, Glassy M
Methods Mol Biol
. 2018 Dec;
1904:401-415.
PMID: 30539482
Pritumumab, a natural human IgG1kappa mAb, was isolated from the regional lymph node of a patient with cervical cancer. This antibody has been reported to bind the cytoskeletal protein vimentin,...